Header Logo

Connection

JOHN KIRKWOOD to Interferon-alpha

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Interferon-alpha.
JOHN KIRKWOOD
Connection Strength
15.236
Interferon-alpha
  1. An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma. Cancer. 2019 09 01; 125(17):3013-3024.
    View in: PubMed
    Score: 0.572
  2. Multiple antigen-engineered DC vaccines with or without IFNa to promote antitumor immunity in melanoma. J Immunother Cancer. 2019 04 24; 7(1):113.
    View in: PubMed
    Score: 0.571
  3. Neoadjuvant ipilimumab (3?mg/kg or 10?mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer. 2018 10 23; 6(1):112.
    View in: PubMed
    Score: 0.551
  4. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-a-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol. 2017 Mar 10; 35(8):885-892.
    View in: PubMed
    Score: 0.489
  5. BRAF Inhibitors and IFNa: Plus, Minus, or Indeterminate? J Natl Cancer Inst. 2016 Jul; 108(7).
    View in: PubMed
    Score: 0.457
  6. Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res. 2014 Apr; 24(2):150-7.
    View in: PubMed
    Score: 0.402
  7. ECOG phase II trial of graded-dose peginterferon a-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602). Clin Cancer Res. 2013 Dec 01; 19(23):6597-604.
    View in: PubMed
    Score: 0.389
  8. IFN-a in the treatment of melanoma. J Immunol. 2012 Oct 15; 189(8):3789-93.
    View in: PubMed
    Score: 0.363
  9. How much of a good thing? What duration for interferon alfa-2b adjuvant therapy? J Clin Oncol. 2012 Nov 01; 30(31):3773-6.
    View in: PubMed
    Score: 0.362
  10. Neoadjuvant therapy for high-risk bulky regional melanoma. J Surg Oncol. 2011 Sep; 104(4):386-90.
    View in: PubMed
    Score: 0.336
  11. Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci. 2009 Dec; 1182:47-57.
    View in: PubMed
    Score: 0.298
  12. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res. 2009 Feb 15; 15(4):1443-51.
    View in: PubMed
    Score: 0.282
  13. Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res. 2008 Dec 15; 14(24):8314-20.
    View in: PubMed
    Score: 0.279
  14. Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma. Cancer Immunol Immunother. 2008 Sep; 57(9):1315-21.
    View in: PubMed
    Score: 0.265
  15. STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy. J Invest Dermatol. 2008 Aug; 128(8):1997-2002.
    View in: PubMed
    Score: 0.264
  16. Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol. 2008 Jan; 5(1):2-3.
    View in: PubMed
    Score: 0.258
  17. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res. 2007 Mar 01; 13(5):1523-31.
    View in: PubMed
    Score: 0.246
  18. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006 Jul 01; 24(19):3164-71.
    View in: PubMed
    Score: 0.235
  19. Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b". Oncologist. 2006 May; 11(5):538-9; author reply 539-40.
    View in: PubMed
    Score: 0.232
  20. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006 Feb 16; 354(7):709-18.
    View in: PubMed
    Score: 0.229
  21. Building upon the standard of care in adjuvant therapy of high-risk melanoma. J Clin Oncol. 2005 Dec 01; 23(34):8559-63.
    View in: PubMed
    Score: 0.224
  22. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004 Mar 01; 10(5):1670-7.
    View in: PubMed
    Score: 0.200
  23. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma. Forum (Genova). 2003; 13(2):127-40; quiz 187-8.
    View in: PubMed
    Score: 0.184
  24. Use and abuse of statistics in evidence-based medicine. J Clin Oncol. 2002 Oct 01; 20(19):4122-3; author reply 4123-4.
    View in: PubMed
    Score: 0.181
  25. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol. 2002 Sep 01; 20(17):3703-18.
    View in: PubMed
    Score: 0.180
  26. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer. 2002 Sep 01; 95(5):1101-12.
    View in: PubMed
    Score: 0.180
  27. Update on adjuvant interferon therapy for high-risk melanoma. Oncology (Williston Park). 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197.
    View in: PubMed
    Score: 0.180
  28. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res. 2002 Aug; 8(8):2480-7.
    View in: PubMed
    Score: 0.179
  29. Cancer immunotherapy: the interferon-alpha experience. Semin Oncol. 2002 Jun; 29(3 Suppl 7):18-26.
    View in: PubMed
    Score: 0.177
  30. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol. 2002 Apr 15; 20(8):2053-7.
    View in: PubMed
    Score: 0.175
  31. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002 Apr; 13(2):119-34.
    View in: PubMed
    Score: 0.175
  32. Interferon alfa-2a for melanoma metastases. Lancet. 2002 Mar 16; 359(9310):978-9.
    View in: PubMed
    Score: 0.174
  33. An update on adjuvant interferon for melanoma. Cancer Control. 2002 Jan-Feb; 9(1):16-21.
    View in: PubMed
    Score: 0.172
  34. Rhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI. J Clin Oncol. 2001 Sep 01; 19(17):3794.
    View in: PubMed
    Score: 0.168
  35. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma. Arch Dermatol. 2001 Sep; 137(9):1217-24.
    View in: PubMed
    Score: 0.168
  36. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001 May 01; 19(9):2370-80.
    View in: PubMed
    Score: 0.164
  37. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol. 2001 Mar 01; 19(5):1430-6.
    View in: PubMed
    Score: 0.162
  38. CTLA-4 blockade and interferon-a induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma. PLoS One. 2021; 16(1):e0245287.
    View in: PubMed
    Score: 0.161
  39. Update on the role of adjuvant interferon for high risk melanoma. Forum (Genova). 2000 Jul-Sep; 10(3):230-9.
    View in: PubMed
    Score: 0.155
  40. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000 Jun; 18(12):2444-58.
    View in: PubMed
    Score: 0.154
  41. Adjuvant interferon in the treatment of melanoma. Br J Cancer. 2000 May; 82(10):1755-6.
    View in: PubMed
    Score: 0.153
  42. CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-a. Front Immunol. 2019; 10:14.
    View in: PubMed
    Score: 0.140
  43. Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med. 1999 Jan; 5(1):11-20.
    View in: PubMed
    Score: 0.140
  44. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-a2b in Advanced Melanoma. Clin Cancer Res. 2019 01 15; 25(2):524-532.
    View in: PubMed
    Score: 0.138
  45. Adjuvant interferon treatment for melanoma. Hematol Oncol Clin North Am. 1998 Aug; 12(4):823-33.
    View in: PubMed
    Score: 0.136
  46. Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies. Eur J Cancer. 1998 Jul; 34 Suppl 3:S12-7.
    View in: PubMed
    Score: 0.135
  47. Adjuvant IFN alpha2 therapy of melanoma. Lancet. 1998 Jun 27; 351(9120):1901-3.
    View in: PubMed
    Score: 0.135
  48. Adjuvant Therapy in Resected Melanoma. N Engl J Med. 2018 02 15; 378(7):679-680.
    View in: PubMed
    Score: 0.131
  49. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. J Natl Cancer Inst. 2018 01 01; 110(1).
    View in: PubMed
    Score: 0.130
  50. High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med. 2017 Nov; 6(11):2576-2585.
    View in: PubMed
    Score: 0.128
  51. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res. 2017 Nov 15; 23(22):6888-6892.
    View in: PubMed
    Score: 0.127
  52. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-a2b in patients with metastatic melanoma. Melanoma Res. 2017 08; 27(4):342-350.
    View in: PubMed
    Score: 0.127
  53. Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: trade-offs between completeness, simplicity and clarity. Eur J Cancer. 1997 Aug; 33(9):1345-6.
    View in: PubMed
    Score: 0.127
  54. Adjuvant interferon-a for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer. 2017 09; 82:171-183.
    View in: PubMed
    Score: 0.126
  55. Interferon adjuvant therapy of melanoma. Cancer. 1997 May 01; 79(9):1843-6.
    View in: PubMed
    Score: 0.124
  56. The adjuvant treatment of malignant melanoma. J Fla Med Assoc. 1997 Mar; 84(3):147-52.
    View in: PubMed
    Score: 0.123
  57. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma. Semin Oncol. 1997 Feb; 24(1 Suppl 4):S16-23.
    View in: PubMed
    Score: 0.122
  58. Adjuvant Therapy of Melanoma. Cancer Treat Res. 2016; 167:181-208.
    View in: PubMed
    Score: 0.113
  59. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan; 14(1):7-17.
    View in: PubMed
    Score: 0.113
  60. Immune checkpoint blockade and interferon-a in melanoma. Semin Oncol. 2015 Jun; 42(3):436-47.
    View in: PubMed
    Score: 0.107
  61. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol. 2014 Nov 20; 32(33):3771-8.
    View in: PubMed
    Score: 0.104
  62. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-a or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother. 2012 Nov-Dec; 35(9):702-10.
    View in: PubMed
    Score: 0.091
  63. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res. 1992 Feb 15; 52(4):851-6.
    View in: PubMed
    Score: 0.087
  64. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol. 2012 Jan 20; 30(3):322-8.
    View in: PubMed
    Score: 0.086
  65. Interferon alpha in combination with other biologics: the scientific rationale. Br J Haematol. 1991 Oct; 79 Suppl 1:78-80.
    View in: PubMed
    Score: 0.085
  66. Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med. 2011 May 05; 9:52.
    View in: PubMed
    Score: 0.082
  67. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother. 2011 Apr; 34(3):270-8.
    View in: PubMed
    Score: 0.082
  68. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 1990 Oct; 8(10):1637-49.
    View in: PubMed
    Score: 0.079
  69. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer. 2010 Sep 15; 116(18):4326-33.
    View in: PubMed
    Score: 0.079
  70. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med. 2010 Aug 16; 8:76.
    View in: PubMed
    Score: 0.078
  71. Interferon alpha-2a and dacarbazine in melanoma. J Natl Cancer Inst. 1990 Jun 20; 82(12):1062-3.
    View in: PubMed
    Score: 0.077
  72. Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol. 2010 Apr; 133(4):646-53.
    View in: PubMed
    Score: 0.076
  73. Next generation of immunotherapy for melanoma. J Clin Oncol. 2008 Jul 10; 26(20):3445-55.
    View in: PubMed
    Score: 0.068
  74. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer. 2008 Mar 01; 112(5):982-94.
    View in: PubMed
    Score: 0.066
  75. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res. 2007 Jun; 17(3):193-200.
    View in: PubMed
    Score: 0.063
  76. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007 Apr 15; 13(8):2422-8.
    View in: PubMed
    Score: 0.062
  77. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005 Jan 01; 23(1):133-41.
    View in: PubMed
    Score: 0.053
  78. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol. 2004 Jan 01; 22(1):11-4.
    View in: PubMed
    Score: 0.049
  79. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer. 2003 Jul 01; 98(1):100-9.
    View in: PubMed
    Score: 0.048
  80. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. Cancer. 2003 Jan 01; 97(1):121-7.
    View in: PubMed
    Score: 0.046
  81. Sentinel lymph node biopsy and adjuvant therapy for melanoma: evidence revisited. Arch Dermatol. 2003 Jan; 139(1):99; author reply 99-100.
    View in: PubMed
    Score: 0.046
  82. Fluorescence imaging analysis of upstream regulators and downstream targets of STAT3 in melanoma precursor lesions obtained from patients before and after systemic low-dose interferon-alpha treatment. Mol Imaging. 2003 Jan; 2(1):65-73.
    View in: PubMed
    Score: 0.046
  83. Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. J Transl Med. 2022 06 03; 20(1):253.
    View in: PubMed
    Score: 0.044
  84. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002 Mar 01; 20(5):1311-8.
    View in: PubMed
    Score: 0.043
  85. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol. 2001 Feb 01; 19(3):812-23.
    View in: PubMed
    Score: 0.040
  86. Dysregulated NF-?B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. Cancer Immunol Res. 2020 12; 8(12):1554-1567.
    View in: PubMed
    Score: 0.040
  87. Biologic therapy. Clin Plast Surg. 2000 Oct; 27(4):643-65.
    View in: PubMed
    Score: 0.039
  88. Cognitive function and quality of life in interferon therapy for melanoma. Clin Nurs Res. 2000 Aug; 9(3):352-63.
    View in: PubMed
    Score: 0.039
  89. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol. 1997 Jun; 15(6):2351-8.
    View in: PubMed
    Score: 0.031
  90. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. Am J Clin Oncol. 1996 Dec; 19(6):546-51.
    View in: PubMed
    Score: 0.030
  91. Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates. J Immunother Emphasis Tumor Immunol. 1996 Nov; 19(6):433-42.
    View in: PubMed
    Score: 0.030
  92. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996 Oct; 14(10):2666-73.
    View in: PubMed
    Score: 0.030
  93. Interferons in melanoma. Curr Opin Oncol. 1996 Mar; 8(2):167-74.
    View in: PubMed
    Score: 0.029
  94. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS One. 2012; 7(7):e40805.
    View in: PubMed
    Score: 0.022
  95. Role of interferons in the therapy of melanoma. J Invest Dermatol. 1990 Dec; 95(6 Suppl):180S-184S.
    View in: PubMed
    Score: 0.020
  96. Meeting report from the Third Global Workshop on Melanoma. Pigment Cell Melanoma Res. 2010 Oct; 23(5):e1-7.
    View in: PubMed
    Score: 0.020
  97. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008 Dec 10; 26(35):5748-54.
    View in: PubMed
    Score: 0.017
  98. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol. 2007 Sep 01; 25(25):3802-7.
    View in: PubMed
    Score: 0.016
  99. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998 May; 16(5):1743-51.
    View in: PubMed
    Score: 0.008
  100. Recent advances in the care of the patient with malignant melanoma. Ann Surg. 1997 Jan; 225(1):1-14.
    View in: PubMed
    Score: 0.008
  101. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1991 Oct; 9(10):1806-10.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.